NCT01865617: A reported trial by Fred Hutchinson Cancer Center
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT01865617 |
|---|---|
| Title | Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | May 22, 2013 |
| Completion date | March 26, 2021 |
| Required reporting date | March 26, 2022, midnight |
| Actual reporting date | March 21, 2022 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |